^
Association details:
| Biomarker: | CLDN18.2 positive |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | satricabtagene autoleucel (CT041) (CLDN18.2-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
Excerpt:
...Immunohistochemistry (IHC) staining of subject's tumor tissue sample is CLDN18.2-positive; 7....
Trial ID:
Source:
Title:
1372O - CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system
Published date:
09/13/2021
Excerpt:
...a total of 37 patients with cancer of digestive system, including 28 with gastric cancer (GC), 5 with pancreatic ductal adenocarcinoma (PDAC) and 4 with other cancer types, received CT041 infusion...The overall ORR for all patients and patients with GC were 48.6% (95%CI, 31.9%, 65.6%) and 57.1% (95%CI, 37.2, 75.5) respectively. At the dose level of 2.5×108, 18 patients with GC who have failed at least 2 prior lines of therapy including 44% (8/18) exposure to anti-PD-(L)1 antibody, the overall ORR, median PFS and OS was 61.1% (11/18), 5.4 months (95%CI, 2.6, NE) and 9.5 months (95%CI, 5.2, NE) respectively. CT041 showed acceptable safety profile and promising anti-tumor activities in patients with refractory CLDN18.2+ cancers of digestive system. In patients with GC who have failed at least 2 prior lines of therapy, CT041 displayed a significantly improved efficacy compared to historical data.
Trial ID:
